Novartis’ Sandoz announces EC approval for HCF Hyrimoz

Sandoz, a Novartis division, announced that the European Commission granted marketing authorization in the European Union for a citrate-free high concentration formulation, or HCF, of its biosimilar Hyrimoz. The approval includes all indications covered by the reference medicine: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa. Rebecca Guntern, Head of Region Europe, Sandoz, said: "With eight marketed biosimilars Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe with more than two decades of experience. Today’s approval brings Sandoz one step closer to providing European patients with chronic conditions an additional treatment option that offers increased convenience and a reduction in injection volume."